James W Hodge Selected Research

Cancer Vaccines

5/2021	Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy.
2/2021	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy.
1/2020	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
10/2017	Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.
12/2016	Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.
2/2016	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
10/2015	ABO blood type correlates with survival on prostate cancer vaccine therapy.
9/2015	A poxviral-based cancer vaccine the transcription factor twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model.
1/2015	Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.
11/2014	Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James W Hodge Research Topics

Disease

113	Neoplasms (Cancer) 12/2021 - 01/2002
23	Carcinoma (Carcinomatosis) 02/2021 - 06/2004
17	Prostatic Neoplasms (Prostate Cancer) 11/2018 - 05/2005
16	Vaccinia 09/2015 - 01/2002
11	Fowlpox 05/2014 - 10/2002
10	Neoplasm Metastasis (Metastasis) 10/2017 - 03/2007
7	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2014
5	Chordoma 12/2021 - 05/2016
4	Mouth Neoplasms (Oral Cancer) 01/2020 - 01/2016
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 04/2017
4	Squamous Cell Carcinoma of Head and Neck 01/2020 - 03/2006
3	Disease Progression 01/2020 - 01/2007
3	Colorectal Neoplasms (Colorectal Cancer) 10/2015 - 09/2002
2	Triple Negative Breast Neoplasms 01/2021 - 04/2016
2	Hematologic Neoplasms (Hematological Malignancy) 07/2020 - 08/2008
2	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 01/2003
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2018 - 02/2012
2	Lung Neoplasms (Lung Cancer) 08/2014 - 06/2008

Drug/Important Bio-Agent (IBA)

54	VaccinesIBA 02/2021 - 01/2002
49	AntigensIBA 12/2021 - 01/2002
23	Cancer VaccinesIBA 05/2021 - 09/2002
15	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 10/2004
15	Carcinoembryonic AntigenIBA 05/2016 - 09/2002
10	Monoclonal AntibodiesIBA 01/2020 - 06/2005
9	Interleukin-15 (Interleukin 15)IBA 12/2021 - 03/2007
8	Immune Checkpoint InhibitorsIBA 05/2021 - 06/2013
8	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 05/2016 - 10/2002
7	avelumabIBA 01/2020 - 06/2016
7	Proteins (Proteins, Gene)FDA Link 10/2017 - 01/2006
6	Immunoglobulin G (IgG)IBA 11/2018 - 06/2016
6	Biological ProductsIBA 01/2014 - 06/2003
6	AutoantigensIBA 01/2006 - 01/2002
5	LigandsIBA 12/2021 - 06/2013
5	Cetuximab (Erbitux)FDA Link 12/2021 - 12/2016
5	Granzymes (Granzyme)IBA 01/2020 - 02/2012
5	PerforinIBA 01/2017 - 09/2002
5	Brachyury protein (Brachyury)IBA 12/2016 - 10/2013
4	Chimeric Antigen ReceptorsIBA 12/2021 - 01/2020
4	ALT-803IBA 01/2021 - 01/2020
4	PlatinumIBA 01/2020 - 09/2011
4	CytokinesIBA 01/2020 - 07/2009
4	Death Domain ReceptorsIBA 01/2020 - 06/2004
4	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 03/2006
4	Interleukin-2 (IL2)IBA 12/2016 - 05/2003
4	CalreticulinIBA 12/2016 - 01/2014
4	enzalutamideIBA 04/2016 - 11/2013
4	PROSTVACIBA 10/2015 - 07/2009
4	B7 AntigensIBA 09/2015 - 10/2002
4	Prostate-Specific Antigen (Semenogelase)IBA 02/2014 - 05/2005
4	CD58 Antigens (LFA-3)IBA 05/2008 - 10/2002
3	AntibodiesIBA 12/2021 - 12/2016
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 02/2021 - 03/2010
3	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2021
3	Docetaxel (Taxotere)FDA Link 01/2021 - 06/2008
3	Histone Deacetylase InhibitorsIBA 01/2020 - 02/2016
3	entinostat (MS 275)IBA 01/2020 - 02/2016
3	Pharmaceutical PreparationsIBA 01/2019 - 06/2008
3	InterleukinsIBA 04/2018 - 03/2007
3	EpitopesIBA 01/2017 - 09/2002
3	Transcription Factors (Transcription Factor)IBA 06/2016 - 10/2013
3	AndrogensIBA 04/2016 - 10/2014
3	Sunitinib (Sutent)FDA Link 01/2015 - 04/2012
3	Synthetic Vaccines (Recombinant Vaccines)IBA 11/2014 - 12/2007
3	Hormones (Hormone)IBA 10/2014 - 01/2007
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 03/2007 - 05/2003
2	B7-H1 AntigenIBA 12/2021 - 01/2021
2	ErbB Receptors (EGF Receptor)IBA 12/2021 - 01/2018
2	Estrogen ReceptorsIBA 01/2021 - 04/2016
2	EnzymesIBA 01/2021 - 05/2014
2	olaparibIBA 01/2020 - 11/2018
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2018 - 02/2016
2	Vorinostat FDA Link 01/2018 - 02/2016
2	Twist-Related Protein 1IBA 10/2017 - 09/2015
2	Protons (Proton)IBA 12/2016 - 05/2016
2	RadiopharmaceuticalsIBA 12/2016 - 07/2008
2	Mucin-1 (CA 15-3 Antigen)IBA 05/2016 - 07/2008
2	abirateroneIBA 04/2016 - 10/2014
2	Androgen Receptors (Androgen Receptor)IBA 04/2016 - 10/2014
2	Androgen Receptor AntagonistsIBA 09/2015 - 11/2013
2	Tyrosine Kinase InhibitorsIBA 01/2015 - 11/2014
2	Sorafenib (BAY 43-9006)FDA Link 01/2015 - 11/2014
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2015 - 11/2014
2	cabozantinibIBA 01/2015 - 11/2014
2	Interferon-gamma (Interferon, gamma)IBA 05/2014 - 09/2002
2	Adenosine Triphosphate (ATP)IBA 01/2014 - 08/2013
2	HMGB1 Protein (HMG1)IBA 01/2014 - 08/2013
2	Vinorelbine (Navelbine)FDA LinkGeneric 02/2012 - 09/2011
2	Fas Ligand Protein (Fas Ligand)IBA 08/2008 - 06/2004
2	Therapeutic UsesIBA 06/2006 - 03/2005
2	Peptides (Polypeptides)IBA 01/2006 - 09/2002
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2021
1	afimoxifene (hydroxytamoxifen)IBA 01/2021

Therapy/Procedure

52	Therapeutics 12/2021 - 01/2003
51	Immunotherapy 12/2021 - 06/2003
16	Radiotherapy 01/2018 - 06/2003
15	Drug Therapy (Chemotherapy) 01/2021 - 01/2006
5	Castration 12/2016 - 07/2009
3	Aftercare (After-Treatment) 01/2016 - 01/2012
2	Immunomodulation 08/2014 - 08/2014
1	Combined Modality Therapy 12/2021